Inventiva (IVA) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Inventiva, a clinical-stage biopharmaceutical company, has reported its total voting rights and shares forming its capital as of November 4, 2024. The company is actively advancing its lead product candidate, lanifibranor, in a Phase 3 clinical trial for MASH/NASH treatment and holds a robust pipeline with additional drug candidates. As a public company listed on Euronext Paris and Nasdaq, Inventiva continues to explore further development opportunities in its field.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
